Meritage Portfolio Management Raises Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Meritage Portfolio Management increased its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 8.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 85,000 shares of the biopharmaceutical company’s stock after purchasing an additional 6,740 shares during the period. Meritage Portfolio Management’s holdings in Sangamo Therapeutics were worth $74,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System lifted its stake in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Sangamo Therapeutics during the 2nd quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth $89,000. Wealth Enhancement Advisory Services LLC grew its holdings in Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares during the period. Finally, Marshall Wace LLP increased its holdings in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 207,476 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. HC Wainwright increased their target price on Sangamo Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company.

Sangamo Therapeutics Trading Down 5.9 %

SGMO stock opened at $2.70 on Tuesday. The stock has a market capitalization of $562.20 million, a P/E ratio of -1.96 and a beta of 1.10. The firm has a 50-day moving average price of $1.20 and a 200-day moving average price of $0.82. Sangamo Therapeutics, Inc. has a 12 month low of $0.29 and a 12 month high of $3.18.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.